Patient leaflet - Porcilis PCV
B. PACKAGE LEAFLET
PACKAGE LEAFLET:
Porcilis PCV emulsion for injection for pigs
-
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch release:
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The NETHERLANDS
-
2. NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis PCV emulsion for injection for pigs
-
3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
Each dose of 2 ml contains:
Porcine circovirus type 2 ORF2 subunit antigen: > 3720 Antigenic Units as determined in the in vitro potency test (AlphaLISA)
Adjuvants:
25 mg dl-a-tocopheryl acetate 346 mg light liquid paraffin.
Emulsion for injection. Opalescent white, with brown resuspendable sediment.
-
4. INDICATION(S)
For the active immunisation of pigs to reduce the virus load in blood and lymphoid tissues and to reduce mortality and weight loss associated with PCV2 infection occurring during the fattening period.
Onset of immunity: 2 weeks
Duration of immunity: 22 weeks.
-
5. CONTRAINDICATIONS
None
-
6. ADVERSE REACTIONS
In laboratory studies and field trials:
Transient local reactions at the injection site were very commonly observed after vaccination mainly in the form of a hard, warm and sometimes painful swelling (diameter up to 10 cm). These reactions resolve spontaneously over a period of approximately 14–21 days without any major consequence on the general health status of the animals. Immediate systemic hypersensitivity-like reactions were commonly observed after vaccination, resulting in minor neurological symptoms such as tremors and/or excitation, which normally resolve within minutes without requiring treatment. A transient increase in body temperature, normally not exceeding 1 °C, was very commonly observed until 2 days after vaccination. In individual animals, an increase of rectal temperature of 2.5 °C lasting less than 24 hours was uncommonly observed.
In some piglets depression and a reduced feed intake for up to 5 days were uncommonly observed. Vaccination may result in a transient impairment of growth rate in the immediate period after administration of the vaccine.
In post marketing experience:
In very rare cases anaphylactic-type reactions can occur, which may be life-threatening. In the event of such reactions, treatment may be needed.
The frequency of adverse reactions is defined using the following convention: – very common (more than 1 in 10 animals treated displaying adverse reactions) – common (more than 1 but less than 10 animals in 100 animals treated) – uncommon (more than 1 but less than 10 animals in 1,000 animals treated) – rare (more than 1 but less than 10 animals in 10,000 animals treated)
-
– very rare (less than 1 animal in 10,000 animals, including isolated reports treated).
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.
-
7. TARGET SPECIES
Pigs.
-
8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Administer one dose (2 ml), by intramuscular injection in the neck in the area behind the ear, according to the following schedule:
In the case of low to medium levels of maternally derived antibodies against PCV2 a single vaccination (2 ml) to pigs from an age of 3 weeks onwards is advised.
When it is expected that higher levels of maternally derived antibodies against PCV2 are present, the following schedule of two vaccinations is advised: the first injection (2 ml) can be given from an age of 3–5 days, the second injection (2 ml) 2–3 weeks later.
High levels of MDA may be expected when sows/gilts are vaccinated against PCV2 virus or when sows/gilts have recently been exposed to high levels of PCV2 virus. In such cases it is advised to perform PCV2 serology, using suitable diagnostics, to select the most appropriate vaccination schedule. In case of doubt, apply the two shot vaccination schedule.
-
9. ADVICE ON CORRECT ADMINISTRATION
Before using the vaccine allow it to reach room temperature (15–25 °C) and shake well before use. Avoid multiple vial broaching.
Use sterile syringes and needles.
Avoid introduction of contamination.
Avoid use of vaccination equipment with rubber parts.
-
10. WITHDRAWAL PERIOD(S)
Zero days.
-
11. SPECIAL STORAGE PRECAUTIONS
Keep out of the sight and reach of children.
Store in a refrigerator (2 °C – 8 °C).
Do not freeze. Protect from light.
Shelf-life after first opening the container: 8 hours.
Do not use this veterinary medicinal product after the expiry date (EXP) which is stated on the carton and the vial.
-
12. SPECIAL WARNING(S)
Special precautions for use in animals:
Vaccinate only healthy animals.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
To the user:
This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.
To the physician:
This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
Pregnancy and lactation :
Do not use during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.
Overdose (symptoms, emergency procedures, antidotes):
Following the administration of a double dose of vaccine no side effects other than those described under “adverse reactions” have been observed.
Incompatibilities:
Do not mix with any other veterinary medicinal product.
-
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
-
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED